"
Team:UCL
From 2013.igem.org
| Line 124: | Line 124: | ||
<div class="large_left"> | <div class="large_left"> | ||
| - | + | <h1>Team Abstract</h1> | |
| + | |||
| + | <p> | ||
| + | The UCL iGEM team of 2013 plans to create a potential treatment for AB plaque related diseases, notably Alzheimer's, the most common form of dementia which costs the UK National Health Service more then Cancer and Stroke treatment combined. The aim is to use ''Microglial'' cells which are part of the brains natural immune defence and subsequently modify these cells to target and break down AB Plaques, which may delay the onset of Alzheimer's disease in patients.The team aims to perform experiments to demonstrate engineered ''Microglial'' cells performing various tasks, including moving towards AB plaques via chemotaxis, as well as breaking down the plaques, which will result in several new parts being required, as well as using other systems previously seen in iGEM and improving them to meet the puroposes of the project. | ||
| + | |||
| + | </p> | ||
| + | |||
</div> | </div> | ||
Revision as of 14:15, 11 July 2013
Team Abstract
The UCL iGEM team of 2013 plans to create a potential treatment for AB plaque related diseases, notably Alzheimer's, the most common form of dementia which costs the UK National Health Service more then Cancer and Stroke treatment combined. The aim is to use ''Microglial'' cells which are part of the brains natural immune defence and subsequently modify these cells to target and break down AB Plaques, which may delay the onset of Alzheimer's disease in patients.The team aims to perform experiments to demonstrate engineered ''Microglial'' cells performing various tasks, including moving towards AB plaques via chemotaxis, as well as breaking down the plaques, which will result in several new parts being required, as well as using other systems previously seen in iGEM and improving them to meet the puroposes of the project.
